
Functional interrogation of US EPA's Toxcast database for identification of hepatotoxic drugs

Sricharan Bandhakavi

In collaboration with EBTC

How to eliminate putatively liver toxic drugs from going into clinical trials/market?



Test

Leverage preclinical/Toxcast data for identifying drugs with potential toxicities to liver

Why Toxcast?

Toxcast* assays represent > 1100 endpoints that cover a range of high-level cell responses

Toxcast has in vitro/cellular assay data for ~ 2000 chemicals including > 500 FDA approved pharmaceutical drugs

Previous work indicates diagnostic potential of Toxcast assay targets/pathways for identification of "mostDILI" drugs (appendix)

^{*}https://www.epa.gov/chemical-research/toxicity-forecasting

Study aim

• Determine what value, if any, does Toxcast provide to existing models of DILI (prediction of "mostDILI" vs "other" DILI class drugs)

Benchmark model LTKB-based logistic regression model

Generate model performance statistics

Compare model performance statistics

Test model Toxcast predictors*
added to benchmark
model predictors

Generate model performance statistics

Toxcast data retrieval/preparation

Obtain AC50 values from <= 1193 Toxcast^{db2} assays for 503 drugs

• Data containing AC50 values loaded into R

Merge Toxcast data with C_{max} & DILI information from LTKB*

• Based on 350 drug matches with C_{max}, 350RX1197C data frame created. Merged also DILI class labels.


Impute missing AC50 values for drug/assay combinations

• 79% of data points set to 10⁶ (indicates no activation of assay by drug)

Calculate Normalized Activation
Score (NAS)** for each
drug/assay combination


 Select all drugs with medium NAS value or higher for further modeling

Normalized Activation Score for stratification of ToxCast test/targets' activation potential in humans




Normalized activation score (NAS)	Indication
NAS>=0	C _{max} > AC50; highest activation potential
0>NAS>-4	C _{max} < AC50; modest activation potential
NAS<-4	C _{max} <<< AC50; lowest activation potential

175/350 drugs selected based on medium NAS value of >=-4 for further analysis/modeling



Pharmacological activity of drugs by DILI class shows relatively low # of Toxcast targets/drug



Data preparation for ML modeling

Generated dataset of 175 drugs consisting of:

- NAS values, corresponding ToxCast tests and their inferred (216) gene targets/pathways
- DILI classification (60 "mostDILI", 115 "other"), drug/chemical name

Convert data to "wide" format:


- NAS values for all 216 ToxCast targets placed alongside each drug name
- Missing NAS values imputed to -1000 (97% data consists of missing values)

Generate/visualize 3 "scaled"* datasets before modeling:

- Current predictors alone (6CX175R) "mc" data**
- ToxCast predictors alone (216CX175R) "tc" data
- Current predictors + ToxCast predictors (223CX175R) "mctc" data

^{*} Scaled using Standard Scaler in sklearn, **Current drug predictors consist of: hydrophobicity/logP, molecular weight, Cmax, daily dose, reactive metabolites (60 missing values for reactive metabolites imputed by literature search; all other values derived from LTKB and provided by Minjun Chen)

Relationship between predictors in scaled "mc" data vs DILI classification (1="mostDILI", 0 = "other")



Relationship between ToxCast predictors vs DILI classification (pre-PCA vs post-PCA)

0.75

- 0.50


- 0.25

- 0.00


-0.25

-0.50

-0.75



Relationship between all predictors and DILI classification (pre-PCA vs post-PCA)



ML modeling strategy

Perform machine learning to predict "mostDILI" vs "other" DILI classification using:

- scaled mc data (benchmark model predictors)
- post-PCA tc data (toxcast predictors)
- post-PCA mctc data (benchmark model predictors + Toxcast predictors)

Evaluate performance of multiple machine learning algorithms*

- Logistic regression, trees/ensemble models (decision tree, random forest, gradient boost), KNN, naïve bayes, support vector machine, to be included
- For all models maximize performance using hyperparameter tuning/gridsearch CV and/or optimization of probability thresholds

Evaluate top (performing) algorithms over multiple test/train data combinations (10-fold cross validation)

- Combine best performing algorithms via voting classifier
- Compare performance of top performers/voting classifier using mctc data vs mc data alone for precision (positive predictive value), recall (sensitivity), specificity, accuracy


^{*} All modeling performed in Python/sklearn package

Top ML algorithms show potential additive effect of ToxCast predictors to "benchmark model/predictors"

Logistic regression

"mctc" has modestly higher TPR relative to "mc" dataset but lower AUC across all probability thresholds


Support vector machine



"mctc" has modestly higher TPR relative to "mc" dataset but lower AUC across all probability thresholds


Best 2 models show additive effect of ToxCast predictors to "benchmark model/predictors"

"Fused"* logistic regression-SVM (best model)




"mctc" has modestly higher TPR relative to "mc" dataset but lower AUC across all probability thresholds

Logistic regression (next best model)




"mctc" has modestly higher TPR relative to "mc" dataset but lower AUC across all probability thresholds

Performance of fused logistic-SVM classifier (best model) with Toxcast predictors vs benchmark model



Logistic regression w/ optimized thresholds and Toxcast predictors vs benchmark model



Conclusions

Toxcast predictors' addition enhances precision, specificity, and accuracy of DILI prediction models

Benchmark
model

Alternative models with Toxcast predictors

Model	Precision	Sensitivity	Specificity	Accuracy
Logistic regression @P>=0.5	0.49	0.64	0.65	0.65
Fused logistic-SVM @P>=0.43	0.54	0.62	0.72	0.69
Logistic regression @P>=0.43	0.52	0.64	0.69	0.67


Value-add of Toxcast predictors to prediction of "mostDILI" drugs vs "other" DILI is quite modest

• There is a need for *alternative predictors* for further enhancing DILI prediction models to be practically useful

Appendix

- Association of Toxcast targets/pathways with DILI classes
- Bayesian probabilities of indicating a "mostDILI" drug for 167 Toxcast targets/pathways

Subset of 216 Toxcast assay targets/pathways are uniquely associated with DILI classes



Perturbation of selected Toxcast targets have elevated probability for indicating a "most DILI" drug

